The stock performance of Jaguar Health, Inc. has shown a fair amount of fluctuation over the last 24 hours. Notably, the company witnessed a significant drop from a high of 0.3465 to a low of 0.225 within the day. However, after hitting the day's lows, the stock made a moderate recovery and closed at 0.2434. The volumes have also indicated a rush of sell-offs, which suggests that investors may be cashing out following recent positive news from the company. The company has been on a stream of positive news developments, ranging from approval of all proposals at the special meeting of stockholders, adoption of a limited duration stockholder rights plan, receiving regulatory clearance in Germany and Italy, to the first patient dosed in the trial of Crofelemer. Despite the bullish news sentiments, external market conditions or perhaps speculation-driven transactions led to its bearish performance in the last 24 hours. It's crucial for investors to watch out for both the company's progress in its trial of Crofelemer and the broader market trends. Strong fundamentals may potentially lead to a reversal in the current bearish trend. Considering the volatility, investors should closely observe key support and resistance levels for signs of a breakout in either direction.